MC & JS

[anonymous]

Dear HQ Clowns: Quit posting these stupid messages!! We don't need to read your advice tips, etc.! Just leave the sales force alone and post your drivel on marketing blogs!! Furthermore, don't show up at our meetings! All you do is eat, get drunk and try to bed reps at the sales meetings - - - big waste of time and money!!

Dear Sales Reps: Distance yourself from people who: 1 speak poorly about others 2 have problems for every solution 3 enjoy complaining 4 always feel entitled 5 blame others for losing 6 take more than give 7 make you feel bad about yourself 8 cheat or lie 9 bully or troll 10 nitpick as a hobby!!

 

[anonymous]

Dear Sales Reps: Distance yourself from people who: 1 speak poorly about others 2 have problems for every solution 3 enjoy complaining 4 always feel entitled 5 blame others for losing 6 take more than give 7 make you feel bad about yourself 8 cheat or lie 9 bully or troll 10 nitpick as a hobby!!

SPOT ON ADVICE!!! THANKS FOR POSTING!

 

[anonymous]

Novartis has to pay 2 weeks per year of employment. So if someone is laid off after being here less than a year, they get crap. They are having OBU backfill as a distraction so we don’t lose momentum in sales. They will protect their own Novartis people which is why their own eyecare and SEE division (specialty eye and ear) have been on a hiring freeze for months leading up to this deal. Xiidra reps will be plugged into openings, and if u land over in SEE division have fun in primary care, there will be some expansion of sales force size, and the rest of us I’d imagine are toast. I would guess that only 50% max of xiidra reps will land actual jobs that last more than a year. And if you think I’m full of $hit, u just don’t know Novartis.

Very likely. Well explained.

 

[anonymous]

Novartis has to pay 2 weeks per year of employment. So if someone is laid off after being here less than a year, they get crap. They are having OBU backfill as a distraction so we don’t lose momentum in sales. They will protect their own Novartis people which is why their own eyecare and SEE division (specialty eye and ear) have been on a hiring freeze for months leading up to this deal. Xiidra reps will be plugged into openings, and if u land over in SEE division have fun in primary care, there will be some expansion of sales force size, and the rest of us I’d imagine are toast. I would guess that only 50% max of xiidra reps will land actual jobs that last more than a year. And if you think I’m full of $hit, u just don’t know Novartis.

They aren't on a hiring freeze. Just hired two new reps here in Chicago.

 

[anonymous]

SPOT ON ADVICE!!! THANKS FOR POSTING!

Spot on. Odd.

 

[anonymous]

They aren't on a hiring freeze. Just hired two new reps here in Chicago.

Those reps have been there a couple months before their hiring freeze.

 

[anonymous]

Those reps have been there a couple months before their hiring freeze.

Lol, ok. Whatever helps you sleep at night

 

[anonymous]

Very likely. Well explained.

This is not a numbers game. Sure they will optimize a bit in time but they dont see Xiidra as an add into a existing bag product. Agree or disagree, fine but thats the reality. They dont have OD presence and they want it and they still want the SOV on the other products and they anticipate product launches and additional late stage acquisition products. Thats the reality. Thats the internal meeting content.

Paranoia is real for some of you. Maybe its time you seek treatment.

When they do optimize it will be talent selection and not "protecting their own" They have an non-tenured sales force now

 

[anonymous]

This is not a numbers game. Sure they will optimize a bit in time but they dont see Xiidra as an add into a existing bag product. Agree or disagree, fine but thats the reality. They dont have OD presence and they want it and they still want the SOV on the other products and they anticipate product launches and additional late stage acquisition products. Thats the reality. Thats the internal meeting content.

Paranoia is real for some of you. Maybe its time you seek treatment.

When they do optimize it will be talent selection and not "protecting their own" They have an non-tenured sales force now

Someone with a rational thought. Novartis spent 5.3 billion on xiidra and its people. For the most part, They’re loyalty will be toward the talent that can get them ROI, not who’s from where. This means reps and managers. In many cases senior leaders don’t stay on. Ie Takeda/shire acquisition. All of Novartis’s eye care went to Shire, Aerie, Allergan and smaller eye outfits. They have zero presence in the OD space along with that community having some beef w Novartis. 60 percent of xiidra scripts come from ODs. Trust me, the people speculating here are bottom-feeders that aren’t in the “know”. If you’re uncomfortable with uncertainty, look for another job, the picture isn’t clear here. If you believe you’re marketable/valuable and want to sell a product that’s innovative( not a reformulated steroid, cyclo, or glaucoma product) in some uncertain times than I would stay. The reality is the people bitching on this site are the reps that sit home and work 10 hours a week. The ones that bitch about MC, the ones that cannot sell and need constant direction, the ones with zero perspective. They want a definitive answer to their fate. Deep down inside they know it’s going to be hard to find another job because they’re more of the same (90s-2000s pharma rep), deliver the message, and do what I say, the rep that KK valued. They’re a dime a dozen. Good luck and understand that no one knows what it’s going to look like in 3-6 months. The speculators have been consistently wrong on everything.

 

[anonymous]

We are just being realistic. We here at Shire have a really bloated sales force.,we’ve all known that from the beginning. We don’t have a ton tenured reps either because many left.

 

[anonymous]

We are just being realistic. We here at Shire have a really bloated sales force.,we’ve all known that from the beginning. We don’t have a ton tenured reps either because many left.[/QUOTE


Exactly. Way too many reps and it’s insane they’re still backfilling on our side. The OD point is valid, but that could justify spots for maybe half the sales force, and what an awful position to only be calling on ODs and lose all relationships with the real eye docs ie our surgeons. And this whole “Novartis takes the best talent regardless of what team you’re on” is so ridiculous. It’s a 3rd party like ZS that makes the decisions, there’s maps, they plug people in, they keep a lean ship, and Novartis has a history of laying off those with higher bases regardless of performance, meaning our side. But hey managers, keep passing that Koolaid around and act like you’re not actively interviewing as well.

 

[anonymous]

Again, You are missing the big picture. Keep your sales rep mentality and negativity and enjoy your misery. I's not product per product for sales force distribution. Its evaluated market potential. Its been made clear to you. If you cant process it then please go get a new job. We can only say it so many ways for you to understand.

They see Xiidra bringing in an additional 1 billion dollars in annual sales at some point. Sorry it doesnt go into a big with 3 other products with a 40% weighting. NVS also expects product launches so they are trying to keep a dug in sales team make it stronger for when they launch the new products that will go to MD and OD They will not want to hire all new reps at that time They want to establish a strong presence for now and the future. You may not believe it but that's what they said. It makes pig picture sense. If those products dont come or get scrapped then you can see a major downsizing. Would it make more sense if I write it in crayon for you?

Now cook a burger, pop a beer and be happy you aren't part of Shikedacom, a company that didnt want us in the first place.

 

[anonymous]

Again, You are missing the big picture. Keep your sales rep mentality and negativity and enjoy your misery. I's not product per product for sales force distribution. Its evaluated market potential. Its been made clear to you. If you cant process it then please go get a new job. We can only say it so many ways for you to understand.

They see Xiidra bringing in an additional 1 billion dollars in annual sales at some point. Sorry it doesnt go into a big with 3 other products with a 40% weighting. NVS also expects product launches so they are trying to keep a dug in sales team make it stronger for when they launch the new products that will go to MD and OD They will not want to hire all new reps at that time They want to establish a strong presence for now and the future. You may not believe it but that's what they said. It makes pig picture sense. If those products dont come or get scrapped then you can see a major downsizing. Would it make more sense if I write it in crayon for you?

Now cook a burger, pop a beer and be happy you aren't part of Shikedacom, a company that didnt want us in the first place.

You are a tool

 

[anonymous]

Someone with a rational thought. Novartis spent 5.3 billion on xiidra and its people. For the most part, They’re loyalty will be toward the talent that can get them ROI, not who’s from where. This means reps and managers. In many cases senior leaders don’t stay on. Ie Takeda/shire acquisition. All of Novartis’s eye care went to Shire, Aerie, Allergan and smaller eye outfits. They have zero presence in the OD space along with that community having some beef w Novartis. 60 percent of xiidra scripts come from ODs. Trust me, the people speculating here are bottom-feeders that aren’t in the “know”. If you’re uncomfortable with uncertainty, look for another job, the picture isn’t clear here. If you believe you’re marketable/valuable and want to sell a product that’s innovative( not a reformulated steroid, cyclo, or glaucoma product) in some uncertain times than I would stay. The reality is the people bitching on this site are the reps that sit home and work 10 hours a week. The ones that bitch about MC, the ones that cannot sell and need constant direction, the ones with zero perspective. They want a definitive answer to their fate. Deep down inside they know it’s going to be hard to find another job because they’re more of the same (90s-2000s pharma rep), deliver the message, and do what I say, the rep that KK valued. They’re a dime a dozen. Good luck and understand that no one knows what it’s going to look like in 3-6 months. The speculators have been consistently wrong on everything.

Agree with your post. However, the bash on KK wasn't warranted and she really did a fine job at Shire.

 

[anonymous]

This is not a numbers game. Sure they will optimize a bit in time but they dont see Xiidra as an add into a existing bag product. Agree or disagree, fine but thats the reality. They dont have OD presence and they want it and they still want the SOV on the other products and they anticipate product launches and additional late stage acquisition products. Thats the reality. Thats the internal meeting content.

Paranoia is real for some of you. Maybe its time you seek treatment.

When they do optimize it will be talent selection and not "protecting their own" They have an non-tenured sales force now

This is false. They do have an OD presence. I run into my old Alcon, now Novartis rep in OD offices ALL THE TIME. He's got the two glaucoma meds and pazeo. I've also seen the post op rep in high Co management offices. So you're wrong

 

[anonymous]

Someone with a rational thought. Novartis spent 5.3 billion on xiidra and its people. For the most part, They’re loyalty will be toward the talent that can get them ROI, not who’s from where. This means reps and managers. In many cases senior leaders don’t stay on. Ie Takeda/shire acquisition. All of Novartis’s eye care went to Shire, Aerie, Allergan and smaller eye outfits. They have zero presence in the OD space along with that community having some beef w Novartis. 60 percent of xiidra scripts come from ODs. Trust me, the people speculating here are bottom-feeders that aren’t in the “know”. If you’re uncomfortable with uncertainty, look for another job, the picture isn’t clear here. If you believe you’re marketable/valuable and want to sell a product that’s innovative( not a reformulated steroid, cyclo, or glaucoma product) in some uncertain times than I would stay. The reality is the people bitching on this site are the reps that sit home and work 10 hours a week. The ones that bitch about MC, the ones that cannot sell and need constant direction, the ones with zero perspective. They want a definitive answer to their fate. Deep down inside they know it’s going to be hard to find another job because they’re more of the same (90s-2000s pharma rep), deliver the message, and do what I say, the rep that KK valued. They’re a dime a dozen. Good luck and understand that no one knows what it’s going to look like in 3-6 months. The speculators have been consistently wrong on everything.

No need to bash on others. I know a lot of people having a blast and making some serious bank while selling those so called "non-innovative" products as you put it. Personally I think the products at Aerie and Kala are innovative.

 

[anonymous]

This is not a numbers game. Sure they will optimize a bit in time but they dont see Xiidra as an add into a existing bag product. Agree or disagree, fine but thats the reality. They dont have OD presence and they want it and they still want the SOV on the other products and they anticipate product launches and additional late stage acquisition products. Thats the reality. Thats the internal meeting content.

Paranoia is real for some of you. Maybe its time you seek treatment.

When they do optimize it will be talent selection and not "protecting their own" They have an non-tenured sales force now

Lol. This is a TOTAL numbers game. You’re absolutely crazy if you think it’s not. It’s business and bottom line.

 

[anonymous]

This is false. They do have an OD presence. I run into my old Alcon, now Novartis rep in OD offices ALL THE TIME. He's got the two glaucoma meds and pazeo. I've also seen the post op rep in high Co management offices. So you're wrong

this.

 

[anonymous]

It cracks me up when people talk about Novartis positively in any sort of topic, but pipeline?! Ha! Other than their retina drug, which is separate from everything and everyone else (they hired TWO internal Alcon eyecare reps) this company hasn’t had a new product in over a decade. It’s all a bunch of recycled patent extenders. And now that even those are all going generic as well, they need xiidra. Don’t believe the pipeline dream. Remember when Xiidra was the first of many drugs we’d be launching with shire? We know how that turned out. Expect worse from Novartis.

Lol. False. Moron.

 

[anonymous]

Someone with a rational thought. Novartis spent 5.3 billion on xiidra and its people. For the most part, They’re loyalty will be toward the talent that can get them ROI, not who’s from where. This means reps and managers. In many cases senior leaders don’t stay on. Ie Takeda/shire acquisition. All of Novartis’s eye care went to Shire, Aerie, Allergan and smaller eye outfits. They have zero presence in the OD space along with that community having some beef w Novartis. 60 percent of xiidra scripts come from ODs. Trust me, the people speculating here are bottom-feeders that aren’t in the “know”. If you’re uncomfortable with uncertainty, look for another job, the picture isn’t clear here. If you believe you’re marketable/valuable and want to sell a product that’s innovative( not a reformulated steroid, cyclo, or glaucoma product) in some uncertain times than I would stay. The reality is the people bitching on this site are the reps that sit home and work 10 hours a week. The ones that bitch about MC, the ones that cannot sell and need constant direction, the ones with zero perspective. They want a definitive answer to their fate. Deep down inside they know it’s going to be hard to find another job because they’re more of the same (90s-2000s pharma rep), deliver the message, and do what I say, the rep that KK valued. They’re a dime a dozen. Good luck and understand that no one knows what it’s going to look like in 3-6 months. The speculators have been consistently wrong on everything.

There’s so much that’s wrong with this, I don’t know where to start.

-they sell glaucoma products, but have zero presence within the OD space? Ok...

-novartis bought the drug. Not the people. If you think they bought the people even when their own reps sell in the same space, you’re crazy. We as a work force was the price to get the drug.

-the number of doctors who have “beef” with novartis over buying Alcon is so minuscule, it’s a stupid argument to use.